<DOC>
	<DOCNO>NCT02784158</DOCNO>
	<brief_summary>The purpose study provide brigatinib patient locally advance and/or metastatic patient ALK+ NSCLC expand access basis due inability meet eligibility criterion on-going recruiting trial , inability participate clinical trial ( e.g. , poor performance status , lack geographic proximity ) , medical intervention consider appropriate acceptable .</brief_summary>
	<brief_title>An Expanded Access Study Brigatinib Patients With ALK-positive Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Have histologically cytologically confirm locally advanced metastatic NSCLC determine ALKrearrangement detect accord local standard procedure . 2 . Resistant intolerant least 1 prior ALK TKI . 3 . Recovered toxicity relate prior anticancer therapy NCI CTCAE , v4.0 ) grade ≤2 . 4 . Are male female patient ≥18 year old . 5 . Have adequate organ hematologic function , define study protocol . 6 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . 7 . Have normal QT interval screen electrocardiogram ( ECG ) evaluation , define QT interval correct ( Fridericia ) ( QTcF ) ≤450 ms male ≤470 ms female . 8 . For female patient childbearing potential , negative pregnancy test must document prior enrollment ( &lt; 7 day prior first dose ) . 9 . Female male patient fertile must agree use highly effective form contraception define study protocol . 10 . Must provide sign date informed consent indicate patient inform pertinent aspect study , include potential risk , willingly participate . 1 . Received ALK TKI within 10 day prior first dose brigatinib . 2 . Received cytotoxic chemotherapy , investigational agent , radiation within 14 day , except stereotactic radiosurgery ( SRS ) stereotactic body radiosurgery . 3 . Received prior brigatinib therapy . 4 . Received monoclonal antibody within 30 day first dose brigatinib . 5 . Had major surgery within 30 day first dose brigatinib . 6 . Have current spinal cord compression . 7 . Have significant , uncontrolled , active cardiovascular disease within 6 month prior first dose , define study protocol . 8 . Have history presence pulmonary interstitial disease , drugrelated pneumonitis , radiation pneumonitis . 9 . Have know suspected hypersensitivity brigatinib excipients . 10 . Have condition illness , opinion investigator , would compromise patient safety . 11 . Are pregnant breastfeeding . 12 . Are eligible reasonable access participate another ongoing brigatinib clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Non-small cell lung carcinoma</keyword>
	<keyword>Epithelial lung cancer</keyword>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>Large cell carcinoma</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Anaplastic lymphoma kinase ( ALK )</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Advanced Cancers</keyword>
	<keyword>Brigatinib</keyword>
	<keyword>AP26113</keyword>
</DOC>